| Market Cap | 11.55M | P/E | - | EPS this Y | -5.10% | Ern Qtrly Grth | - |
| Income | -19.51M | Forward P/E | -0.77 | EPS next Y | 26.00% | 50D Avg Chg | -1.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -8.00% |
| Dividend | N/A | Price/Book | 0.43 | EPS next 5Y | - | 52W High Chg | -53.00% |
| Recommedations | 2.00 | Quick Ratio | 2.12 | Shares Outstanding | 9.40M | 52W Low Chg | 20.00% |
| Insider Own | 1.15% | ROA | -39.89% | Shares Float | 9.28M | Beta | 2.01 |
| Inst Own | 4.47% | ROE | -91.37% | Shares Shorted/Prior | 463.39K/449.13K | Price | 1.27 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 30,024 | Target Price | 12.00 |
| Oper. Margin | - | Earnings Date | May 9 | Volume | 17,513 | Change | 0.79% |
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. It also develops ThermoDox, a direct chemotherapy. In addition, the company is developing IMNN-101, a COVID-19 booster vaccine which is in preclinical trials; IMNN-102 for the of the Lassa virus which is in preclinical trials; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. Further, it develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase and will focus on the development of personalized cancer vaccines, or neoepitope cancer vaccines. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
| HC Wainwright & Co. | Buy | Apr 1, 24 |
| HC Wainwright & Co. | Buy | Mar 13, 24 |
| HC Wainwright & Co. | Buy | Sep 15, 23 |
| HC Wainwright & Co. | Buy | Aug 11, 23 |
| HC Wainwright & Co. | Buy | May 12, 23 |
| Alliance Global Partners | Buy | Oct 13, 22 |